Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
NovaBay Pharmaceuticals Inc Receives Additional FDA 510 Clearance For NeutroPhase Wound Cleanser
NovaBay Pharmaceuticals Inc announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) to market NeutroPhase Skin and Wound Cleanser under widened indications including the moistening and debriding of graft and donor sites. Concurrently, the FDA cleared NeutroPhase to be administered through a new convenient spray pump.
Latest Developments for NovaBay Pharmaceuticals Inc
Latest Key Developments in Biotechnology
- Venaxis Inc Announces Pricing Of Offering Of Common Stock And Warrants
- Elan Corporation PLC Rejects Latest Royalty Pharma Approach-WSJ
- Apricus Biosciences Inc Prices $17.1 Million Public Offering Of Common Stock And Warrants
- Stemline Therapeutics Inc Announces Exercise Of Option To Purchase Additional Shares
- Share this
- Link this
- Digg this
Follow Reuters